Access the full text.
Sign up today, get DeepDyve free for 14 days.
W. Grove (1981)
Statistical Methods for Rates and Proportions, 2nd edAmerican Journal of Psychiatry, 138
J. McCullough (2000)
TRANSFUSION in the New YearTransfusion, 40
(1999)
Données Sur la Couverture Vaccinale Au 31 Décembre 1998
Larry Mimms, J. Mosley, Hollinger Fb, R. Aach, C. Stevens, M. Cunningham, D. Vallari, L. Barbosa, George Nemo (1993)
Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection.British Medical Journal, 307
A. Couroucé, J. Pillonel, C. Saura (1999)
Screening of blood donations for HTLV-I/II.Transfusion medicine reviews, 13 4
J. Pillonel, A. Couroucé, C. Saura, J. Desenclos (2001)
[Impact of the exclusion of donors who have stayed in the United Kingdom on the residual risk of HIV transmission by blood transfusion].Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 8 2
A. Couroucé (1999)
Sensibilité des trousses de dépistage des anticorps anti-VIH. Réévaluation 1999Transfusion Clinique Et Biologique, 6
Couroucé Am, J. Pillonel (1996)
Transfusion-transmitted viral infections. Retrovirus and Viral Hepatitis Working Groups of the French Society of Blood Transfusion.The New England journal of medicine, 335 21
A. Couroucé, J. Pillonel, C. Saura (2000)
Dépistage des marqueurs des infections transmissibles par transfusion sur les dons collectés en France de 1996 à 1998Transfusion Clinique Et Biologique, 7
Miriam Alter, D. Kruszon-Moran, O. Nainan, G. Mcquillan, Fengxiang Gao, L. Moyer, Richard Kaslow, H. Margolis (1999)
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.The New England journal of medicine, 341 8
C. Saura, A. Couroucé, J. Pillonel, D. Costagliola, B. Flan, C. Defer, J. Coste, C. Rouzioux (1999)
Risk-benefit analysis of nucleic acid testing: the French experience.Biologicals : journal of the International Association of Biological Standardization, 27 4
Michael Busch, Kevin Watanabe, James Smith, Sigurd Hermansen, Ruth Thomson (2000)
False‐negative testing errors in routine viral marker screening of blood donorsTransfusion, 40
E. Murphy, S. Bryzman, Williams Ae (1999)
Prevalence of hepatitis C virus infection in the United States.The New England journal of medicine, 341 27
Couroucé Couroucé, Pillonel Pillonel, Saura Saura (2000)
(Screening for markers of infections transmitted by transfusions in blood collected in France from 1996 to 1998) (English abstract).Transfus Clin Biol, 7
M. Alter, H. Margolis (1998)
Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
R. Janssen, G. Satten, S. Stramer, B. Rawal, T. O'Brien, B. Weiblen, F. Hecht, N. Jack, F. Cleghorn, J. Kahn, M. Chesney, M. Busch (1998)
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.JAMA, 280 1
Durand Durand, Beauplet Beauplet, Marcellin Marcellin (2000)
Evidence of hepatitis C virus viremia without detectable antibody to hepatitis C virus in a blood donor.Ann Intern Med, 133
W. Hughes, A. Barr, B. Dow, E. Follett, J. Barbara (1995)
A multicentre assessment of the specificity of ten anti‐HBc screening testsTransfusion Medicine, 5
M. Vilayleck (2002)
The WHO European Region declared free of polio.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 7 5
J. Barrera, B. Francis, G. Ercilla, M. Nelles, D. Achord, J. Darner, S. Lee (1995)
Improved Detection of Anti‐HCV in Post‐Transfusion Hepatitis by a Third‐Generation ELISAVox Sanguinis, 68
M. Montalbano, Jolene Jenkins (1996)
Persistent lack of detectable HIV-1 antibody in a person with HIV infection--Utah, 1995.MMWR. Morbidity and mortality weekly report, 45 9
S. Laperche, M. Maniez-Montreuil, A. Couroucé (2000)
Les tests de dépistage combiné de l'antigène p24 et des anticorps anti-VIH dans l'infection précoce à VIH-ITransfusion Clinique Et Biologique, 7
F. Pont, D. Costagliola, A. Valleron, C. Rouzioux (1995)
Correction: How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?Transfusion, 36
W. Koch, P. Sullivan, C. Roberts, Kori Francis, R. Downing, T. Mastro, J. Nkengasong, D. Hu, S. Masciotra, C. Schable, R. Lal (2001)
Evaluation of United States-Licensed Human Immunodeficiency Virus Immunoassays for Detection of Group M Viral VariantsJournal of Clinical Microbiology, 39
F. Dubois, J. Desenclos, N. Mariotte, A. Goudeau (1997)
Hepatitis C in a French population‐based survey, 1994: Seroprevalence, frequency of viremia, genotype distribution, and risk factorsHepatology, 25
L. Petersen, Glen Satten, R. Dodd, M. Busch, Steve Kleinman, A. Grindon, B. Lenes (1994)
Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibodyTransfusion, 34
M. Busch, L. Lee, G. Satten, D. Henrard, H. Farzadegan, K. Nelson, S. Read, R. Dodd, L. Petersen (1995)
Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donorsTransfusion, 35
R. Dodd, S. Stramer, J. Aberle‐grasse, E. Notari (2000)
Risk of hepatitis and retroviral infections among blood donors and introduction of nucleic acid testing (NAT).Developments in biologicals, 102
A. Manns, R. Wilks, E. Murphy, G. Haynes, J. Figueroa, M. Barnett, B. Hanchard, W. Blattner (1992)
A prospective study of transmission by transfusion of HTLV‐I and risk factors associated with seroconversionInternational Journal of Cancer, 51
(2000)
The yield of nucleic acid testing ( NAT ) for HIV and HCV RNA in a population of U . S . voluntary donors : relationship to contemporary measures of incidence ( abstract )
M. Rapicetta, S. Dettori, L. Kondili, P. Chionne, A. Ciccaglione, M. Miceli, E. Mannella (1999)
Persistence of HCV–RNA in a Blood Donor with Negative Antibody AssaysVox Sanguinis, 76
G. Vyas, S. Cohen, R. Schmid (1978)
Viral hepatitis : a contemporary assessment of etiology, epidemiology, pathogenesis, and prevention : proceedings of the Second Symposium on Viral Hepatitis, University of California, San Francisco, March 16-19, 1978
Rapport de l'Observatoire de la Vaccination Contre L'hépatite B. Paris: Sofres/Smith Kline Beecham
H. Alter, L. Seeff (2000)
Recovery, Persistence, and Sequelae in Hepatitis C Virus Infection: A Perspective on Long-Term OutcomeSEMINARS IN LIVER DISEASE, Volume 20
I. Bux-Gewehr, S. Schmandt, R. Zotz, R. Scharf, M. Roggendorf (2001)
Long‐term hepatitis C seroconversion in a blood donorTransfusion, 41
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study.The New England journal of medicine, 334 26
Barbara Peoples, S. Preston, J. Tzeng, S. Stramer, L. Gifford, M. Wissel (2000)
Prolonged antibody‐negative HCV viremia in a US blood donor with apparent HCV transmission to a recipientTransfusion, 40
(2000)
Screen- ing tests combined with p 24 antigen and anti-HIV anti- bodies in early detection of HIV-1] (English abstract)
T. Ly, S. Laperche (2001)
Early Detection of Human Immunodeficiency Virus Infection Using Third- and Fourth-Generation Screening AssaysEuropean Journal of Clinical Microbiology and Infectious Diseases, 20
Kleinman Kleinman, Busch Busch, Holland Holland (1992)
Post‐transfusion hepatitis C virus infection (letter).N Engl J Med, 327
J. Pillonel, C. Saura, A. Couroucé (1998)
Screening of viral markers for HIV HBV and HCV infections in blood donors in France and residual risk of viral transmission by blood transfusion.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 3 7
J. Pillonel, A. Couroucé, C. Saura, J. Desenclos (2001)
Impact de l’exclusion des donneurs ayant séjournédans les îles britanniques sur le risque résiduel de transmission du VIH par transfusion de produits sanguins labilesTransfusion Clinique Et Biologique, 8
Steven Kleinman, M. Busch, P. Holland (1992)
Post-transfusion hepatitis C virus infection.The New England journal of medicine, 327 22
(1996)
Recommandations pour la désinfection des endoscopes
Couroucé Couroucé, Et Le Groupe De Travail Rétrovirus de la Société Nationale de Transfusion Sanguine Et Le Groupe De Travail Rétrovirus de la Société Nationale de Transfusion Sanguine (1993)
(HIV seropositivity in blood donors from 1990 to 1992: prevalence, estimation of residual risk of transfusion‐related infections and epidemiology) (English abstract).Rev Fr Transfus Hémobiol, 36
A. Couroucé, J. Pillonel (1998)
Risque de transmission d’infections virales par transfusion de dérivés sanguins labiles, 3
É. Couturier, F. Damond, P. Roques, H. Fleury, F. Barin, J. Brunet, F. Brun-vezinet, F. Simon (2000)
HIV-1 diversity in France, 1996–1998AIDS, 14
Glynn Glynn, Kleinman Kleinman, Schreiber Schreiber (2001)
Viral incidence and prevalence, 1991 to 1998 (abstract). The NHLBI Retrovirus Epidemiology Donor Study (REDS).Transfus Clin Biol, 8
J. Fleiss (1973)
Statistical methods for rates and proportions
G. Schreiber, M. Busch, S. Kleinman, J. Korelitz (1996)
The Risk of Transfusion-Transmitted Viral InfectionsThe New England Journal of Medicine, 334
(1978)
Serologic responses in hepatitis
Couroucé Couroucé (1999)
(Sensitivity of anti‐HIV screening assays: Reevaluation 1999.) The Retrovirus Working Group of the French Society of Blood Transfusion (English abstract).Transfus Clin Biol, 6
C. Schable, C. Pau, D. Hu, T. Dondero, G. Schochetman, H. Jaffe, J. George, L. Zekeng, L. Kaptue, J. Tsague, Lutz Gürtler (1994)
Sensitivity of United States HIV antibody tests for detection of HIV-1 group O infectionsThe Lancet, 344
Evolving applications of nucleic acid amplification assays for prevention of virus transmission by blood components and derivatives
É. Couturier, F. Damond, P. Roques, H. Fleury, F. Barin, J. Brunet, F. Brun-vezinet, F. Simon (2000)
HIV-1 diversity in France, 1996-1998. The AC 11 laboratory network.AIDS, 14 3
F. Pont, D. Costagliola, C. Rouzioux, A. Valleron (1995)
How much would the safety of blood transfusion be improved by including p24 antigen in the battery of tests?Transfusion, 35
Petersen Petersen, Satten Satten, Dodd Dodd (1994)
Duration of time from onset of HIV type 1 infectiousness to development of detectable antibody. HIV Seroconversion Study Group.Transfusion, 34
A. Couroucé (1993)
[HIV seropositivity in blood donors from 1990 to 1992: prevalence, estimation of residual risk of transfusion-related infections and epidemiology].Revue francaise de transfusion et d'hemobiologie : bulletin de la Societe nationale de transfusion sanguine, 36 4
(2000)
Long-Term Prevention of Bone Loss
(1991)
abstract). The NHLBI Retrovirus Epidemiology Donor Study (REDS)
Recommandations pour la désinfection des endoscopes Recommandations pour la désinfection des endoscopes (1996)
Circulaire DGS/DH no. 236 du 2 avril 1996.Bull Epidémiol Hebdomadaire, 22
J. Korelitz, M. Busch, S. Kleinman, A.E. Williams, R. Gilcher, H. Ownby, G. Schreiber (1997)
A method for estimating hepatitis B virus incidence rates in volunteer blood donors. National Heart, Lung, and Blood Institute Retrovirus Epidemiology Donor StudyTransfusion, 37
MMWR Morbid Mortal Week Rep, 47
I. Loussert‐Ajaka, F. Brun-vezinet, F. Simon, T. Ly, M. Chaix, S. Saragosti, A. Couroucé, D. Ingrand (1994)
HIV-1/HIV-2 seronegativity in HIV-1 subtype 0 infected patientsThe Lancet, 343
T. Legler, J. Riggert, G. Simson, Cornelia Wolf, Andreas Humpe, U. Munzel, A. Uy, M. Köhler, K. Heermann (2000)
Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion‐transmitted HCV infectionTransfusion, 40
T. Fong, A. Bisceglie, R. Biswas, J. Waggoner, L. Wilson, Janet Claggett, J. Hoofnagle (1994)
High levels of viral replication during acute hepatitis B infection predict progression to chronicityJournal of Medical Virology, 43
A. Couroucé (1993)
Séropositivité VIH chez les donneurs de sang de 1990 à 1992 : prévalence, estimation du risque résiduel d'infections transfusionnelles et épidémiologieRevue Française de Transfusion et d'Hémobiologie, 36
Busch Busch, Watanabe Watanabe, Smith Smith (2000)
False‐negative testing errors in routine viral marker screening of blood donors. The Retrovirus Epidemiology Donor Study.Transfusion, 40
BACKGROUND : Monitoring trends in residual risks of transfusion‐transmitted viral infections (HIV, HTLV, HBV, and HCV) is important to assess improvements in blood safety. In France, theses trends were analyzed between 1992 and 2000. STUDY DESIGN AND METHODS : As risk is predominantly associated with the window period, residual risks were estimated by multiplying incidence rates by the durations of the window periods. Incidence rates were calculated from the data collected by the blood transfusion centers belonging to the Transfusion‐Transmissible Agents Working Group, which currently collects more than 50 percent of the 2.5 million blood samples donated each year in France. RESULTS : Trend analysis showed a significant decrease in residual risks for HCV (p = 0.01) and HBV (p < 0.001). Although residual risks decreased for HIV and HTLV, the trends were not significant. In 1998 through 2000, residual risks were estimated to be 1 in 470,000 donations for HBV, 1 in 860,000 for HCV, 1 in 1,370,000 for HIV, nil for HTLV, and 1 in 250,000 for the four viruses combined. CONCLUSION S: In France, the current risk of a blood recipient becoming infected with a retrovirus or a hepatitis virus is extremely low. The implementation of NAT in July 2001 is predicted to reduce the residual risk to 1 in 2,700,000 donations for HIV and 1 in 8,300,000 for HCV.
Transfusion – Wiley
Published: Aug 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.